NewsOne Featured Video


LONDON – U.S. drug firm Endo Pharmaceuticals’ gel designed to prevent infection with the AIDS virus has proved ineffective in trials in Africa, Britain’s Medical Research Council (MRC) said on Monday.

A large international trial of vaginal microbicide Pro 2000 in more than 9,000 women in four African countries found no evidence that it reduces the risk of HIV infection.

The result is a setback for the specialty drugmaker, whose shares were hit earlier in the month when U.S. health regulators declined to approve its Aveed drug for low testosterone.

Click here to read more.


HIV-Positive Husband Injects Sleeping Wife With Infected Blood

Obama Administration Criticized On AIDS Program

More from NewsOne